Fan Heng, Zhu Jian-Hua, Yao Xue-Qing
Heng Fan, Department of Intensive Care Unit, Ningbo First Hospital, Ningbo, China, Department of General Surgery, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
Jian-hua Zhu, Department of Intensive Care Unit, Ningbo First Hospital, Ningbo, China.
Pak J Med Sci. 2016 Nov-Dec;32(6):1568-1573. doi: 10.12669/pjms.326.11511.
The co-stimulatory molecule B7-H3 plays an important role in prognosis of several malignancies. However, its prognostic value in clinic in patient with colorectal cancer (CRC) is still controversial. This meta-analysis evaluated the relationship between B7-H3 expression and the outcomes of CRC patients.
PubMed, Google Scholar, Embase, CNKI and Wanfang database were searched for the studies on the relationship between the expression of B7-H3 and prognosis of CRC patients. Pooled odds ratios (ORs) analysis with 95% confidence interval (95% CIs) for lymph node metastasis, 24-month overall survival and 72-month overall survival were performed mainly using Review Manager 5.0.
Six articles including 1,202 total CRC cases were included for the meta-analysis. Pooled analysis with fixed-effects model showed that B7-H3 expression had no relationship with lymphatic metastasis in CRC patients (Fixed-effects, OR= 1.18; 95 % CI:0.87-1.61, P=0.28). However, B7-H3 expression was associated with 24-month overall survival (Fixed-effects, OR=0.48, 95% CI:0.32-0.74, P<0.001) and 72-month overall survival (Fixed-effects, OR = 0.61, 95% CI: 0.43-0.85, P< 0.01) in CRC patients.
The co-stimulatory molecule B7-H3 expression is negatively associated with lymph node metastasis in CRC. However, B7-H3 detection might be a feasible and effective means to predict the prognosis in CRC patients.
共刺激分子B7-H3在多种恶性肿瘤的预后中起重要作用。然而，其在结直肠癌（CRC）患者临床中的预后价值仍存在争议。本荟萃分析评估了B7-H3表达与CRC患者预后之间的关系。
检索PubMed、谷歌学术、Embase、中国知网和万方数据库中关于B7-H3表达与CRC患者预后关系的研究。主要使用Review Manager 5.0对淋巴结转移、24个月总生存率和72个月总生存率进行合并比值比（OR）分析，并计算95%置信区间（95%CI）。
纳入6篇文章，共1202例CRC病例进行荟萃分析。固定效应模型的合并分析显示，B7-H3表达与CRC患者的淋巴转移无关（固定效应，OR = 1.18；95%CI：0.87 - 1.61，P = 0.28）。然而，B7-H3表达与CRC患者的24个月总生存率（固定效应，OR = 0.48，95%CI：0.32 - 0.74，P < 0.001）和72个月总生存率（固定效应，OR = 0.61，95%CI：0.43 - 0.85，P < 0.01）相关。
共刺激分子B7-H3表达与CRC患者的淋巴结转移呈负相关。然而，检测B7-H3可能是预测CRC患者预后的一种可行且有效的方法。
